A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia

British Journal of Haematology

Volumn 161, Issue 6, 2013, Pages 794-801

  Kennedy, Glen A ^a,b   Morris, Kirk L ^a   Subramonpillai, Elango ^a   Curley, Cameron ^a   Butler, Jason ^a   Durrant, Simon ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute myeloid leukaemia; Deferasirox; Ferritin; Haematopoietic progenitor cell transplantation; Iron overload

Indexed keywords

C REACTIVE PROTEIN; CYTARABINE; DEFERASIROX; FERRITIN; IDARUBICIN; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROCOLITIS; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; IRON OVERLOAD; LIVER FUNCTION TEST; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TYPHLITIS; URINARY TRACT INFECTION;

ADULT; AGED; BENZOATES; BLOOD TRANSFUSION; CONSOLIDATION CHEMOTHERAPY; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FERRITINS; HUMANS; IATROGENIC DISEASE; INDUCTION CHEMOTHERAPY; IRON CHELATING AGENTS; IRON OVERLOAD; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84878506400     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12319     Document Type: Article

References (38)

1. Alessandrino, E.P., Della Porta, M.G., Bacigalupo, A., Malcovati, L., Angelucci, E., Van Lint, M.T., Falda, M., Onida, F., Bernardi, M., Guidi, S., Lucarelli, B., Rambaldi, A., Cerretti, R., Marenco, P., Pioltelli, P., Pascutto, C., Oneto, R., Pirolini, L., Fanin, R. & Bosi, A. (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica, 95, 476-484.
2. Altès, A., Remacha, A.F., Sureda, A., Martino, R., Briones, J., Canals, C., Brunet, S., Sierra, J. & Gimferrer, E. (2002) Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplantation, 29, 987-989.
3. Armand, P., Kim, H.T., Cutler, C.S., Ho, V.T., Koreth, J., Alyea, E.P., Soiffer, R.J. & Antin, J.H. (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood, 109, 4586-4588.
4. Armand, P., Kim, H.T., Rhodes, J., Sainvil, M.-M., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., Hearsey, D., Neufeld, E.J., Fleming, M.D., Steen, H., Anderson, D., Kwong, R.Y., Soiffer, R.J. & Antin, J.H. (2011) Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biology of Blood and Marrow Transplantation, 17, 852-860.
5. Armand, P., Sainvil, M.-M., Kim, H.T., Rhodes, J., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., Neufeld, E.J., Kwong, R.Y., Soiffer, R.J. & Antin, J.H. (2012) Does iron overload really matter in stem cell transplantation? American Journal of Hematology, 87, 569-572.
6. Armand, P., Sainvil, M.-M., Kim, H.T., Rhodes, J., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., Neufeld, E.J., Kwong, R.Y., Soiffer, R.J. & Antin, J.H. (2013) Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplantation, 48, 146-147.
7. Bishop, J.F., Lowenthal, R.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, M.G., Kronenberg, H., Ma, D. & Dodds, A. (1990) Etoposide in acute nonlymphocytic leukemia Australian Leukemia Study Group. Blood, 75, 27-32.
8. Bishop, J.F., Matthews, J.P., Young, G.A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M. & Fox, R. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]. Blood, 87, 1710-1717.
9. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, P., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P. & Albert, D. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107, 3455-3462.
10. Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Löwenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
11. Fröhling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H. & Döhner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372-4380.
12. Gattermann, N., Finelli, C., Porta, M.D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B. & Rose, C. (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leukemia Research, 34, 1143-1150.
13. Gattermann, N., Jarisch, A., Schlag, R., Blumenstengel, K., Goebeler, M., Groschek, M., Losem, C., Procaccianti, M., Junkes, A., Leismann, O. & Germing, U. (2012) Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. European Journal of Haematology, 88, 260-268.
14. Kataoka, K., Nannya, Y., Hangaishi, A., Imai, Y., Chiba, S., Takahashi, T. & Kurokawa, M. (2009) Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 15, 195-204.
15. Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H.A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., Rummel, M., Nachbaur, D., Schlegelberger, B., Göhring, G., Späth, D., Morlok, C., Zucknick, M., Ganser, A., Döhner, H. & Schlenk, R.F. (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood, 117, 2137-2145.
16. Khan, F.A., Fisher, M.A. & Khakoo, R.A. (2007) Association of hemochromatosis with infectious diseases: expanding spectrum. International Journal of Infectious Diseases, 11, 482-487.
17. Kim, Y.R., Kim, J.S., Cheong, J.-W., Song, J.W. & Min, Y.H. (2008) Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematologica, 120, 182-189.
18. Kontoghiorghes, G.J., Kolnagou, A., Skiada, A. & Petrikkos, G. (2010) The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin, 34, 227-239.
19. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
20. Lee, J.W., Kang, H.J., Kim, E.K., Kim, H., Shin, H.Y. & Ahn, H.S. (2009) Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplantation, 44, 793-797.
21. Lee, S.H., Yoo, K.H., Sung, K.W., Koo, H.H., Kwon, Y.J., Kwon, M.M., Park, H.J., Park, B.-K., Kim, Y.Y., Park, J.A., Im, H.J., Seo, J.J., Kang, H.J., Shin, H.Y. & Ahn, H.S. (2010) Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Bone Marrow Transplantation, 45, 1287-1293.
22. Lim, Z.Y., Fiaccadori, V., Gandhi, S., Hayden, J., Kenyon, M., Ireland, R., Marsh, J., Ho, A.Y.L., Mufti, G.J. & Pagliuca, A. (2010) Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leukemia Research, 34, 723-727.
23. List, A.F., Baer, M.R., Steensma, D.P., Raza, A., Esposito, J., Martinez-Lopez, N., Paley, C., Feigert, J. & Besa, E. (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. Journal of Clinical Oncology, 30, 2134-2139.
24. Mahindra, A., Bolwell, B., Sobecks, R., Rybicki, L., Pohlman, B., Dean, R., Andresen, S., Sweetenham, J., Kalaycio, M. & Copelan, E. (2009a) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 146, 310-316.
25. Mahindra, A., Sobecks, R., Rybicki, L., Pohlman, B., Dean, R., Andresen, S., Kalaycio, M., Sweetenham, J., Bolwell, B. & Copelan, E. (2009b) Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplantation, 44, 767-768.
26. Majhail, N.S., Lazarus, H.M. & Burns, L.J. (2010) A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biology of Blood and Marrow Transplantation, 16, 832-837.
27. Maradei, S.C., Maiolino, A., de Azevedo, A.M., Colares, M., Bouzas, L.F. & Nucci, M. (2009) Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood, 114, 1270-1275.
28. Morado, M., Ojeda, E., Garcia-Bustos, J., Aguado, M.J., Arrieta, R., Quevedo, E., Navas, A. & Hernandez-Navarro, F. (2000) BMT: serum ferritin as risk factor for veno-occlusive disease of the liver Prospective cohort study. Hematology, 4, 505-512.
29. Ozyilmaz, E., Aydogdu, M., Sucak, G., Aki, S.Z., Ozkurt, Z.N., Yegin, Z.A. & Kokturk, N. (2010) Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplantation, 45, 1528-1533.
30. Parkkila, S., Niemelä, O., Savolainen, E.R. & Koistinen, P. (2001) HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion, 41, 828-831.
31. Pauw, B.D., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., Pappas, P.G., Maertens, J., Lortholary, O., Kauffman, C.A., Denning, D.W., Patterson, T.F., Maschmeyer, G., Bille, J., Dismukes, W.E., Herbrecht, R., Hope, W.W., Kibbler, C.C., Kullberg, B.J., Marr, K.A., Munoz, P, Odds, F.C., Perfect, J.R., Restrepo, A., Ruhnke, M., Segal, B.H., Sobel, J.d., Sorrell, T.C., Viscoli, C., Wingard, J.R., Zaoutis, T, & Bennett, J.E. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clinical Infectious Diseases, 46, 1813-1821.
32. Platzbecker, U., Bornhäuser, M., Germing, U., Stumpf, J., Scott, B.L., Kröger, N., Schwerdtfeger, R., Böhm, A., Kobbe, G., Theuser, C., Rabitsch, W., Valent, P., Sorror, M.L., Ehninger, G. & Deeg, H.J. (2008) Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biology of Blood and Marrow Transplantation, 14, 1217-1225.
33. Pullarkat, V. (2009) Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood, 114, 5251-5255.
34. Pullarkat, V., Blanchard, S., Tegtmeier, B., Dagis, A., Patane, K., Ito, J. & Forman, S.J. (2008) Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 42, 799-805.
35. Sivgin, S., Eser, B., Bahcebasi, S., Kaynar, L., Kurnaz, F., Uzer, E., Pala, C., Deniz, K., Ozturk, A., Cetin, M. & Unal, A. (2011) Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT). Annals of Hematology, 91, 743-749.
36. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075-4083.
37. Storey, J.A., Connor, R.F., Lewis, Z.T., Hurd, D., Pomper, G., Keung, Y.K., Grover, M., Lovato, J., Torti, S.V., Torti, F.M. & Molnár, I. (2009) The transplant iron score as a predictor of stem cell transplant survival. Journal of Hematology & Oncology, 2, 44.
38. Veneri, D., Franchini, M., Zanetti, F., Krampera, M., de Matteis, G. & Pizzolo, G. (2003) Iron overload in acute myeloid leukemia patients is not related to HFE and TFR2 gene mutations. Haematologica, 88, 1069-1070.